Development of Insulin-like peptide 5 (INSL5) peptide analogues as novel therapeutics. Insulin-like peptide 5 (INSL5) is a naturally-occurring hormone in the body that likely plays a role in the control of appetite. This project aims to develop new molecules based on INSL5 that could be suitable for use as drugs to treat various appetite-related disorders, such as obesity (where patients eat too much) or anorexia (where patients eat too little).
Grafted peptide constructs - a new platform for delivering stable bioactive peptides. The project will develop a new strategy to overcome the lack of bioavailability of peptides. The project will design an effective drug delivery vehicle and facilitate drug development as highly active peptides will become attractive drug targets.
New technology for the delivery of peptide-based T-cell vaccines for tumour immunotherapy. This project is dedicated to finding simple methods for vaccinating humans and animals against a wide variety of cancers. Should this be achieved millions of Australians will be protected from the devastating consequences of cancer. Consequently there will be great benefits socially, medically and economically.
New stable and specific mimics of T cell epitopes for tumor immunotherapy. This project is dedicated to finding simple methods for vaccinating humans and animals against a wide variety of cancers. Should this be achieved millions of Australians will be protected from the devastating consequences of cancer. Consequently there will be great benefits socially, medically and economically.
Development of novel therapies for the treatment of cancer. Both aging and obesity are significant risk factors for cancer and are becoming a burden on the health care budget. The proposed novel cancer therapy will improve current cancer treatments by enhancing their efficacy, thereby reducing the required dose and minimizing side effects. Such an outcome would not only benefit the well being of the individual but would achieve significant health care cost savings.
Modulation of protein folding pathways: a new platform technology for molecular medicine. Misfolding of proteins is becoming recognised as a major cause of inherited disease. We propose to develop a chemical agent that will optimise the folding of alpha1-antitrypsin (AAT), misfolding of which gives rise to inheritable liver and lung disease. This agent will have potential application as a therapy for sufferers of AAT-misfolding disease and for improving the yield of AAT purified from human plasm ....Modulation of protein folding pathways: a new platform technology for molecular medicine. Misfolding of proteins is becoming recognised as a major cause of inherited disease. We propose to develop a chemical agent that will optimise the folding of alpha1-antitrypsin (AAT), misfolding of which gives rise to inheritable liver and lung disease. This agent will have potential application as a therapy for sufferers of AAT-misfolding disease and for improving the yield of AAT purified from human plasma, which is the current agent used to treat patients with AAT-misfolding disease.Read moreRead less
New insulins for the improved management of diabetes. The prevalence of diabetes has increased dramatically over the past few decades and now this condition is widely considered the world’s fastest growing disease. New insulins with improved pharmacological and storage properties are desperately needed, and this project will work on chemical synthesis enabling designer insulins to be prepared for improved management of diabetes.
DEEP DRILLING OF THE HUMAN PLASMA PROTEOME. Like turning out city lights lets you see the faint stars more clearly - removal of high abundance proteins from human biofluids allows quantum leaps in biomarker discovery. This project will develop products that remove the biggest obstacle in proteomics - high abundance proteins (city lights). Cheap, efficient and routine removal of abundant proteins will amplify the power of ?cutting edge? proteomic technologies in the discovery of novel biomarkers ....DEEP DRILLING OF THE HUMAN PLASMA PROTEOME. Like turning out city lights lets you see the faint stars more clearly - removal of high abundance proteins from human biofluids allows quantum leaps in biomarker discovery. This project will develop products that remove the biggest obstacle in proteomics - high abundance proteins (city lights). Cheap, efficient and routine removal of abundant proteins will amplify the power of ?cutting edge? proteomic technologies in the discovery of novel biomarkers. This is possible because undiscovered low copy number biomarkers (faint stars) exist in human diagnostic fluids at levels far lower than current proteomic array detection limits.Read moreRead less
Characterisation of plant cysteine proteases with therapeutic potential. This project aims to uncover how plant enzymes have effects on the immune system. This will allow the development of these enzymes as therapeutic agents for cancer and autoimmune conditions.
The first integrated multimodal assay for the ultrasensitive detection of dengue contamination of blood. This project will develop the first screening test to check for dengue contamination of blood donations in Australia. This will help ensure safe, continued supply from blood donors, particularly in Queensland where dengue is on the rise.